Tejara Capital Ltd Purchases 108,500 Shares of Certara, Inc. $CERT

Tejara Capital Ltd lifted its position in shares of Certara, Inc. (NASDAQ:CERT) by 39.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 381,552 shares of the company’s stock after acquiring an additional 108,500 shares during the quarter. Certara makes up approximately 0.8% of Tejara Capital Ltd’s portfolio, making the stock its 25th biggest position. Tejara Capital Ltd owned 0.24% of Certara worth $3,361,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. First Horizon Corp bought a new position in Certara in the third quarter valued at about $30,000. Versant Capital Management Inc boosted its stake in shares of Certara by 66.7% during the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after purchasing an additional 1,153 shares in the last quarter. Osaic Holdings Inc. grew its holdings in shares of Certara by 50.7% during the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after purchasing an additional 1,175 shares during the last quarter. Global Retirement Partners LLC grew its holdings in shares of Certara by 45.0% during the third quarter. Global Retirement Partners LLC now owns 5,636 shares of the company’s stock worth $69,000 after purchasing an additional 1,749 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in shares of Certara by 499.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock valued at $69,000 after buying an additional 4,930 shares during the period. Institutional investors own 73.96% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on CERT. BMO Capital Markets dropped their price objective on shares of Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Tuesday. TD Cowen reissued a “buy” rating on shares of Certara in a report on Thursday, February 26th. Morgan Stanley decreased their price target on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a research report on Tuesday. Robert W. Baird dropped their price target on shares of Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Tuesday. Finally, Leerink Partners reissued an “outperform” rating and issued a $10.00 price objective on shares of Certara in a research note on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Certara has an average rating of “Hold” and a consensus price target of $8.85.

Certara Price Performance

Certara stock opened at $4.61 on Friday. The stock’s 50 day moving average is $6.07 and its 200 day moving average is $7.85. Certara, Inc. has a one year low of $4.59 and a one year high of $13.88. The firm has a market cap of $717.18 million, a P/E ratio of -46.10 and a beta of 1.53. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 2.05.

Certara (NASDAQ:CERT) last released its earnings results on Monday, May 11th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. The firm had revenue of $106.92 million for the quarter, compared to analyst estimates of $106.13 million. During the same period in the prior year, the company posted $0.14 EPS. The business’s revenue for the quarter was up .8% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. As a group, research analysts expect that Certara, Inc. will post 0.29 EPS for the current year.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.